Because of the wide variety of mental health concerns and needs of the CF population, the Cystic Fibrosis Foundation has formed the Prioritizing Research in Mental Health (PRIME) Working Group, which is dedicated to mental health research.
Site Search
The Cystic Fibrosis National Resource Centers provide study sponsors and investigators centralized expertise in
This program is intended to facilitate research that will contribute to the development of new therapies or therapeutic strategies to treat cystic fibrosis with an emphasis on advancing CFTR gene repair and replacement approaches.
Through efficient study design, optimized clinical trial execution, and high-quality data, the Therapeutics Development Network (TDN) helps speed the delivery of new and better therapies to people with cystic fibrosis.
Some genetic diseases, such as cystic fibrosis, are caused by mutations in a single gene. A gene contains DNA “letters” that spell out the instructions to make a specific protein. When the protein isn't made correctly, it can lead to a cascade of problems.
Since the launch of the Infection Research Initiative in 2018, the Cystic Fibrosis Foundation has funded more than $100 million in research to improve the detection, diagnosis, treatment, and outcomes of CF-related infections.
The Drug Development Pipeline features an extensive list of drugs that are in development or approved for treating cystic fibrosis. For a drug or program to be shown on the pipeline, it must meet certain conditions.
This competition provides one year of free lab and office space at Bakar Labs at the University of California Berkeley to awardees with emerging genetic medicines delivery technology that may be applied to CF.
The Cystic Fibrosis Foundation is aggressively pursuing potential treatments for people with CF who have nonsense and rare mutations who will not benefit from drugs known as modulators, which correct the malfunctioning cystic fibrosis transmembrane conductance regulator (